StockData
RenovoRx, Inc. logo

RenovoRx, Inc. (RNXT) income statement

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.04+0.09 (+8.91%)

Close on Nov 17, 2026Market cap $46.93MP/E –Yield –

RenovoRx, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
84.4%
Operating margin
-685.2%
Net margin
-621.7%
Return on equity, FY2025
-225.6%

Financial strength

Current ratio
5.74
Debt to equity
–
Debt to assets
–
Cash to current liabilities
503.1%

Valuation

P/E ratio
–
Price to sales
23.75
Price to book
5.23
Dividend yield
–

See a number that looks wrong?